key: cord-0928171-doby3g1y
authors: Kuloğlu, Zeynep Ece; El, Rojbin; Guney‐Esken, Gulen; Tok, Yeşim; Talay, Zeynep Gülçe; Barlas, Tayfun; Kuskucu, Mert Ahmet; Albayrak, Özgür; Doğan, Özlem; Yavuz, Serap Şimşek; Midilli, Kenan; Ergönül, Önder; Can, Füsun
title: Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS‐CoV‐2: A longitudinal study
date: 2022-05-02
journal: Allergy
DOI: 10.1111/all.15316
sha: a0f27fe5744757c1baa42ea816dd2055c64add57
doc_id: 928171
cord_uid: doby3g1y

BACKGROUND: It is essential to know about immune response levels after booster doses of the two different types of vaccines, mRNA, and the inactivated, currently used against COVID‐19. For this purpose, we aimed to determine the effects of BNT162b2 (BNT) and CoronaVac (CV) boosters on the humoral and cellular immunity of individuals who had two doses of CV vaccination. METHODS: The study was conducted in three centers (Koc University Hospital, Istanbul University Cerrahpasa Hospital, and Istanbul University, Istanbul Medical School Hospital) in Istanbul, Turkey. Individuals who had been previously immunized with two doses of CV and no history of COVID‐19 were included. The baseline blood samples were collected 3–5 months after the second dose of CV. Follow‐up blood samples were taken 1 and 3 months after administration of third doses of CV, or one dose of BNT boosters. Neutralizing antibody titers were measured by plaque reduction assay. The CD4+ T cell, CD8+ T cell, effector CD4+CD38+CD69+ T cell, and effector CD8+CD38+CD69+ T cell ratios were determined by flow cytometry. The intracellular IFN‐γ and IL‐2 responses were measured by ELISpot assay. RESULTS: We found a 3.38‐fold increase in neutralizing antibody geometric mean titers (NA GMT, 78.69) 1 month after BNT booster and maintained at the third month (NA GMT, 80). Nevertheless, in the CV booster group, significantly lower NA GMT than BNT after 1 month and 3 months were observed (21.44 and 28.44, respectively) (p < .001). In the ELISpot assay, IL‐2 levels after BNT were higher than baseline and CV booster (p < .001) while IFN‐γ levels were significantly higher than baseline (p < .001). The CD8+CD38+CD69+ and CD4+CD38+CD69+ T cells were stimulated predominantly in the third month of the BNT boosters. CONCLUSION: The neutralizing antibody levels after 3 months of the BNT booster were higher than the antibody levels after CV in fully vaccinated individuals. On the contrary, ratio of the effector T cells increased along with greater IFN‐γ activation after BNT booster. By considering the waning immunity, we suggest a new booster dose with BNT for the countries that already had two doses of primary CV regimens.

The worldwide use of effective and safe COVID-19 vaccines is still a high priority to control the pandemic and to reduce the burden of COVID-19. The vaccine type and vaccination schedule affect many of the cellular and molecular elements of innate and adaptive immune systems.

Estimation of the immune responses after SARS-CoV-2 vaccinations is one of the important parameters in order to predict the efficacy of booster vaccines. Therefore, testing the effectiveness of COVID-19 vaccines in different vaccination schedules is necessary as there are a variety of vaccine availabilities, worldwide. Following primary vaccination, antibody and T-cell responses have decreased over time. 1 A booster dose being administered 6 months after the second dose of various vaccines significantly increased neutralizing antibody concentrations. 2 The heterologous vaccine regimens were reported to stimulate neutralizing antibodies more than the homologous vaccine protocols. 3 In Turkey, the inactivated vaccine CoronaVac (Sinovac Life Sciences) was the first vaccine to receive approval by the Ministry of Health. Healthcare workers and individuals over the age of 65 were suggested two doses of CV administered 2 months apart in the initial phase of the vaccination program. 4 After 6 months, the Ministry of Health of Turkey recommended a booster of BNT as an alternative option to the CV booster. In early studies of the CV, effectiveness after two-dose schedules was reported as 60%-90%. 4, 5 Nevertheless, these studies were performed approximately 6 weeks after the second dose. Six months after the second dose of CV, neutralizing antibody titers declined below the seropositivity cut-off value while a remarkable increase in the neutralizing antibody concentrations was observed with the administration of a third dose. 6 However, our knowledge on the humoral and cellular immune responses obtained by BNT and CV boosters following two doses of primary CoronVac vaccination is still limited. In this study, we aimed to explore the neutralizing antibody and T-cell responses after the booster doses of CV and BNT following two doses of CV.

The neutralizing antibody levels after 3 months of the BNT booster were higher than the antibody levels after CV in fully vaccinated individuals. On the contrary, ratio of the effector T cells increased along with greater IFNγ activation after BNT booster. By considering the waning immunity, we suggest a new booster dose with BNT for the countries that already had two doses of primary CV regimens.

This study determines the effects of BNT162b2 (BNT) and CoronaVac (CV) boosters on the humoral and cellular immunity of individuals who had two doses of CV vaccination. The neutralizing antibody levels after 3 months of the BNT booster are higher than the antibody levels after CV in fully vaccinated individuals. The ratio of the effector T cells increases along with greater IFNγ activation after BNT booster.

The study was conducted in three centers (Koç University Hospital, Istanbul University Cerrahpasa Hospital, and Istanbul University, The peripheral blood mononuclear cells (PBMC) were isolated by Ficoll density gradient centrifugation method, 7 and the cells were stored at the −80°C 8 until use for flow cytometry and ELISpot assays. The sera were stored at the −80°C for neutralizing antibody tests.

Humoral and cellular immune responses were examined to compare the serum SARS-CoV-2 neutralizing antibody titers and T-cell reactivity in PBMC. 

For T-cell assays, 2 × 10 6 PBMCs were seeded in RPMI 1640 media supplemented with 5% AB serum for the wells of the 96 well plates. 

After obtaining sufficient longitudinal data, the statistical analysis of paired samples was performed by using a Wilcoxon signed rank test for the comparison of two dependent groups. For comparison of independent groups, for example, biontech vs. coronavac at first and 3 months, unpaired non-parametric test, Wilcoxon rank-sum (Mann-Whitney) test was performed. GraphPad Prism 8.0.2 Software was used for the analysis and visualization of the obtained data. In statistical analysis STATA 16v (USA) was used, and statistical significance was set as p < .05.

The demographic characteristics of the participants were presented in Table 1 . (Figure 4) .

vaccine booster doses was done by phenotyping S-specific CD4+ and CD8+ T cells. Representative gating was shown in Figure S1 .

One month after the BNT booster, both CD8+CD38+CD69+

T cells and CD4+CD38+CD69+ T cells were stimulated. There was no significant difference compared with baseline levels whereas a significant increase was detected at the third month. After 3 months, the proportion of CD8+CD38+CD69+

T cells increased from baseline of 1.160% to 3.130% (p = .031) and CD4+CD38+CD69+ T cells from 4.37% of baseline to 10% (p = .013). Three months after the CV booster, CD4+CD38+CD69+

T cells increased from 4.37% of baseline to 10.20% (p = .12) and CD8+CD38+CD69+ T cells increased from 1.160% to 3.130% (p = .62) ( Figure 5 ).

The present study addresses the lack of knowledge on the immuno- about the weak immunogenicity would be increased by considering the reduced efficacy of vaccines against the Omicron variant. 14, 15 Current vaccine trials have focused on the stimulation of the neutralizing antibody against SARS-CoV-2, but CD4+ and CD8+ cells also might provide protection from severe disease and support resolution of COVID-19. 16 In our cohort, the magnitude of post BNT booster responses was higher than the CV booster. We CD4 T-cell responses to BNT were reported in clinical studies. 17, 18 The induction of T-cell responses after CV vaccination was also reported by a study from Hong Kong. 19 T-cell clones against other SARS-CoV-2 antigens such as N protein can also be stimulated with inactivated vaccines. 20 The type of peptide pool used for activation might have affected the results of T-cell response measurements. 21 In this study, rather than using peptides of the virus, we used S-pool, which might lead to the underestimation of the true magnitude of T-cell responses. fourth doses after 2 months. Moreover, we could not cover the newly emerged Omicron variant, and this will be done in future studies.

Our study has implications for the countries that have used a two-dose regimen of CV. The neutralizing antibody levels after 3 months of the BNT booster were higher than the antibody levels after the CV booster. On the contrary, the ratio of the effector CD8+ and CD4+ T cells was increased along with greater IFNγ activation after the BNT booster. Taking into consideration the waning immunity, we suggest a second booster dose with BNT for the individuals who already had BNT or CV boosters as their third doses following two doses of CV.

Koc University Isbank Center for Infectious Diseases (KUISCID) funded the study.

The authors declare no conflict of interest in relation to this work. 

Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study

Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Isolation of whole mononuclear cells from peripheral blood and cord blood

Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection

Trimmed Spearman-Karber method for estimating median lethal concentrations in toxicity bioassays

Two detailed plaque assay protocols for the quantification of infectious SARS-CoV-2

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine

A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2. medRxiv

Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients

Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: the Dominican Republic Experience

Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine. Vaccines (Basel)

Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong

CD8(+) T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine

Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: prospective observational study